Form 4: Nautilus CFO Granted 160,000 Stock Options

Nautilus Biotechnology's CFO and Treasurer, Anna Mowry, was granted 160,000 stock options with an exercise price of $2.32 per share, vesting over time.

Summary

• Anna Mowry, the Chief Financial Officer and Treasurer of Nautilus Biotechnology, Inc. (NAUT), was granted 160,000 stock options.
• The options have an exercise price of $2.32 per share.
• The options are set to expire on March 2, 2036.
• Vesting for the options commences on January 1, 2026, with 25% of the shares vesting on the one-year anniversary (January 1, 2027).
• Following the initial vesting, one thirty-sixth (1/36th) of the remaining shares will vest each month thereafter.
• The vesting is contingent upon Ms. Mowry's continuous status as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value and retaining key talent.

Positives

• The grant of stock options aligns the financial interests of the CFO with the long-term performance and shareholder value creation of Nautilus Biotechnology.
• The multi-year vesting schedule serves as an incentive for the retention of key management personnel, promoting stability in leadership.

Future Outlook

The vesting schedule, extending over several years with an expiration date in 2036, indicates a long-term incentive structure designed to retain the CFO and align her performance with the company's future growth and strategic objectives.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the CFO is a standard practice in the biotechnology sector, particularly for growth-oriented companies such as Nautilus Biotechnology. This compensation structure is widely used to attract and retain top talent in a highly competitive industry, directly linking executive incentives to the company's stock performance and long-term success.

Comparison to Industry Standards

• The grant of 160,000 stock options to a CFO is within the typical range for a company of Nautilus Biotechnology's size and stage in the biotech industry, comparable to grants observed at emerging biotech firms.
• An exercise price of $2.32, which is likely the market price on the grant date, is a standard practice for incentive stock options.
• The 4-year vesting schedule (1-year cliff followed by monthly vesting) is a common industry practice for executive compensation, similar to those implemented by established biotech companies, designed to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential for future dilution upon option exercise, balanced by the potential for increased long-term company value driven by aligned executive incentives.
• Employees: Signals continued investment in executive talent and adherence to established compensation frameworks, which can positively impact morale and retention.
• Management: Provides a significant long-term incentive for the CFO, aligning her financial interests directly with the company's success and strategic goals.

Next Steps

• Anna Mowry's continued employment as a 'Service Provider' is required for the options to vest.
• Monthly vesting of the remaining shares will occur after January 1, 2027.
• Anna Mowry may exercise the options if the stock price exceeds $2.32 per share before the expiration date of March 2, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not provide new information that would fundamentally alter the investment thesis for Nautilus Biotechnology. It reinforces management's long-term alignment but does not introduce new operational or financial data to warrant a change in investment stance. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Nautilus Biotechnology, NAUT, Stock Option, Form 4, Anna Mowry, CFO, Executive Compensation, Equity Incentive Plan, Vesting